- Home
- CZNC vs ALLO Comparison
CZNC vs ALLO Comparison
Compare CZNC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ALLO |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 452.6M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CZNC | ALLO |
|---|---|---|
| Price | $27.61 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 46.6K | ★ 5.3M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $4.97 | $255.46 |
| P/E Ratio | $32.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.87 | $1.04 |
| 52 Week High | $26.73 | $4.46 |
Technical Indicators
Market Signals| Indicator | CZNC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 76.41 | 25.84 |
| Support Level | $25.09 | $1.22 |
| Resistance Level | N/A | $2.22 |
| Average True Range (ATR) | 0.62 | 0.08 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 100.00 | 25.00 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).